Treatment of rheumatoid arthritis (RA)-related interstitial lung disease (ILD) is challenging, and many conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) have been associated with ILD development or progression. The aim of this multicentric retrospective study was to analyze the evolution of ILD in Italian RA-ILD patients treated with abatacept (ABA).
Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study / Cassone, Giulia; Manfredi, Andreina; Atzeni, Fabiola; Venerito, Vincenzo; Vacchi, Caterina; Picerno, Valentina; Furini, Federica; Erre, Gian Luca; Tomietto, Paola; Fedele, Anna Laura; Della Casa, Giovanni; Nucera, Valeria; Giannitti, Chiara; Salvarani, Carlo; Sebastiani, Marco. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 9:1(2020), pp. 277-277. [10.3390/jcm9010277]
Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study
Cassone, GiuliaWriting – Original Draft Preparation
;Manfredi, AndreinaWriting – Review & Editing
;Vacchi, CaterinaData Curation
;Della Casa, GiovanniWriting – Review & Editing
;Salvarani, CarloSupervision
;Sebastiani, Marco
Writing – Review & Editing
2020
Abstract
Treatment of rheumatoid arthritis (RA)-related interstitial lung disease (ILD) is challenging, and many conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) have been associated with ILD development or progression. The aim of this multicentric retrospective study was to analyze the evolution of ILD in Italian RA-ILD patients treated with abatacept (ABA).File | Dimensione | Formato | |
---|---|---|---|
Cassone abatacept 2020 jcm.pdf
Open access
Descrizione: Articolo principale
Tipologia:
Versione pubblicata dall'editore
Dimensione
647.12 kB
Formato
Adobe PDF
|
647.12 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris